When Hathi Ram Chaudhary says in his world-weary manner, ‘hum toh paatal lok ke permanent niwasi hain’, he’s not just addressing a character in the series. He’s plunging us into the nether-world again ...

Taking centre stage are exclusive iterations of the Penny, Wander and Arcadie bags, which come with current ‘it girl’ accessories, playful bag charms such as a crochet-knit serpent and, in select ...

RAHWAY, N.J., January 16, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings ...

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 16, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...

Prior to this, SHARP fell under Army Regulation 600-20, Army Command Policy, and according to one of the 21st Theater Sustainment Command sexual assault response coordinators, Laiza Correa Sboron ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

Wendy A. Brown has received honoraria from Johnson and Johnson, GORE, Novo Nordisc, Pfizer, Medtronic, Eli Lilly and Merck Sharpe and Dohme for lectures and advisory boards. She receives research ...

New Jersey-based Merck, which does business outside of the United States as Merck Sharp & Dohme, said that China's National Medical Products Administration (NMPA) last week approved GARDASIL [Human ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...